MongoDB stock drops about 4% in late trade as software sector slides — what’s next for MDB
2 January 2026
1 min read

MongoDB stock drops about 4% in late trade as software sector slides — what’s next for MDB

New York, January 2, 2026, 15:34 ET — Regular session

  • MongoDB fell with other software names even as the broader market held steady.
  • Wall Street opened 2026 cautious on valuations and the rate outlook.
  • Next week’s U.S. jobs report and inflation data are key tests for growth-stock sentiment.

MongoDB, Inc. shares slid about 4% in afternoon trading on Friday, falling to around $402 and underperforming the broader market as software stocks weakened on the first trading day of 2026.

The move matters because MongoDB trades like a classic “risk-on” software stock — the kind that can swing hard when investors reassess valuations and interest-rate expectations. “Stocks trade expensive on 18 of 20 measures,” Bank of America equity and quant strategist Savita Subramanian wrote in a note. 1

Software was a notable drag: the iShares Expanded Tech-Software Sector ETF fell about 2.6%, while the SPDR S&P 500 ETF was up roughly 0.2% and the Invesco QQQ was little changed. Snowflake, Datadog and Elastic were also lower in afternoon trading.

MongoDB sells database software used to store and manage application data, and it competes in a crowded market for enterprise data infrastructure. 2

The stock swung sharply on the day, rising early before reversing lower and testing a round-number support level near $400 as sellers took control.

Next week’s U.S. economic calendar could set the tone for growth stocks, with the monthly jobs report due January 9 and the consumer price index report due January 13, Reuters reported. 3

For software shares, those releases matter because interest-rate expectations feed directly into how investors value future earnings — the faster the expected growth, the more sensitive the stock often is to shifts in rates.

Investors are also looking ahead to MongoDB’s next earnings update. MarketBeat’s earnings calendar estimates the next report for March 4, based on the company’s past reporting schedule. 4

On the company calendar, MongoDB is slated to hold a MongoDB.local event in San Francisco on January 15 that it says will include product announcements and a keynote — an item some investors may watch for new signals on product direction. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next
Previous Story

Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next

Synopsys stock rises nearly 3% today as Loop Capital lifts target to $600; SNPS outperforms peers
Next Story

Synopsys stock rises nearly 3% today as Loop Capital lifts target to $600; SNPS outperforms peers

Go toTop